{
    "name": "pegvaliase",
    "comment": "Rx",
    "other_names": [
        "Palynziq",
        "pegylated phenylalanine ammonia lyase (PAL)",
        "pegvaliase-pqpz"
    ],
    "classes": [
        "Enzymes",
        "Metabolic"
    ],
    "source": "https://reference.medscape.com/drug/palynziq-pegvaliase-1000207",
    "pregnancy": {
        "common": [
            "Based on findings in studies of pregnant animals without phenylketonuria (PKU), pegvaliase-pqpz may cause fetal harm when administered to a pregnant woman",
            "Limited available data with pegvaliase-pqpz use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes",
            "Risks to the fetus associated with poorly controlled phenylalanine concentrations in women with PKU during pregnancy include increased risk for miscarriage, major birth defects (eg, microcephaly, major cardiac malformations), intrauterine fetal growth restriction, and future intellectual disability with low IQ; therefore, closely phenylalanine concentrations in women with PKU during pregnancy",
            "Advise pregnant women of the potential risks to the fetus"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "A reproduction study in pregnant rabbits treated with pegvaliase-pqpz demonstrated a high incidence of fetal malformations throughout the skeletal system, and in kidneys, lungs, and eyes",
                    "Embryo-fetal toxicity (increased resorptions and reduced fetal weight) was also observed",
                    "These effects occurred at 7.5 times the maximum recommended daily dose and were associated with strong signs of maternal toxicity, including marked reductions in weight gain and food consumption, and death",
                    "A reproduction study in pregnant rats treated with pegvaliase-pqpz demonstrated an increase in skeletal variations, with no malformations observed; effects in rats occurred at 4.2 times the maximum recommended daily dose",
                    "In a prenatal/postnatal development study in rats, pegvaliase-pqpz produced reduced survival of offspring during lactation, decreases in pup weight and litter size, and delayed sexual maturation of offspring when administered daily at 19.4 times the maximum recommended daily dose; effects on rat embryo-fetal and postnatal development were associated with maternal toxicity"
                ]
            },
            {
                "type": "Disease-associated maternal and/or embryo-fetal risk",
                "description": [
                    "Uncontrolled blood phenylalanine concentrations before and during pregnancy are associated with an increased risk of adverse pregnancy outcomes and fetal adverse effects; to reduce the risk of hyperphenylalaninemia-induced fetal adverse effects, blood phenylalanine concentrations should be maintained between 120-360 micromol/L during pregnancy and during the 3 months before conception"
                ]
            },
            {
                "type": "Dose adjustments during pregnancy and the postpartum period",
                "description": [
                    "Phenylalanine concentrations <30 micromol/L in pregnant women with PKU may be associated with adverse fetal outcomes; monitor blood phenylalanine concentrations during pregnancy and adjust dose or modify dietary protein and phenylalanine intake to avoid blood phenylalanine concentrations below 30 micromol/L (see Dosage Modifications)"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of pegvaliase-pqpz in human milk, the effects on the breastfed infant, or the effects on milk production",
            "A prenatal/postnatal study in rats showed that pegvaliase-pqpz is present in rat milk and that administration of pegvaliase-pqpz during lactation decreased pup weight and survival"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Anaphylaxis",
                    "description": [
                        "Anaphylaxis reported after administration and may occur at any time during treatment",
                        "Administer the initial dose after an anaphylaxis episode under the supervision of a healthcare provider equipped to manage anaphylaxis, and closely observe >60 minutes following injection",
                        "Prior to self-injection, confirm patient competency with self-administration, and patient’s and observer’s (if applicable) ability to recognize signs and symptoms of anaphylaxis and administer autoinjectable epinephrine, if needed",
                        "Prescribe autoinjectable epinephrine, and instruct patient and observer (if applicable) on how to recognize the signs and symptoms of anaphylaxis, how to properly administer autoinjectable epinephrine, and to seek immediate medical care upon its use",
                        "Consider a caregiver for patients who may need assistance in recognizing and managing anaphylaxis",
                        "If an caregiver is needed, present caregiver during and for >60 minutes after each administration should be able to administer autoinjectable epinephrine, and to call for emergency medical support upon its use",
                        "Consider the risks and benefits of readministering pegvaliase-pqpz following an episode of anaphylaxis",
                        "If treatment is readministered, administer the first dose under the supervision of a healthcare provider equipped to manage anaphylaxis and closely observe >60 minutes following the dose",
                        "Because of the risk of anaphylaxis, treatment is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called Palynziq REMS"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "In clinical trials with induction/titration/maintenance dosing, 26 (9%) of 285 patients experienced a total of 37 anaphylaxis episodes (see Black Box Warnings)",
                "Management of hypersensitivity reactions should be based on severity of reaction, recurrence of reaction, and clinical judgment of healthcare provider, and may include dosage adjustment, temporary drug interruption, or treatment with antihistamines, antipyretics, and/or corticosteroids"
            ],
            "specific": [
                {
                    "type": "REMS program",
                    "description": [
                        "Treatment is available only through a restricted program under Palynziq REMS, because of the risk of anaphylaxis",
                        "Hypersensitivity reactions, other than anaphylaxis, reported",
                        "Requirements of the REMS program",
                        "Prescribers must be certified with the program by enrolling in the program and completing training",
                        "Prescribers must prescribe autoinjectable epinephrine",
                        "Pharmacies must be certified with the program and must dispense only to patients who are authorized to receive treatment",
                        "Patients must enroll in the program and be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment",
                        "Patients must have autoinjectable epinephrine available at all times",
                        "Further information, including a list of qualified pharmacies, is available at www.PALYNZIQREMS.com or by telephone 1-855-758-REMS (1-855-758-7367)"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies",
                        "Risk of coadministration with different PEGylated products is unknown; however, there is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350",
                        "Carefully read all drug labels, including OTC drugs to check contents for PEG"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "pegvaliase, certolizumab pegol. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "Factor IX, recombinant",
            "description": {
                "common": "pegvaliase, Factor IX, recombinant. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "griseofulvin",
            "description": {
                "common": "pegvaliase, griseofulvin. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Applies to ultramicrosized griseofulvin containing PEG 400 and 8000. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methoxy polyethylene glycol / epoetin beta",
            "description": {
                "common": "pegvaliase, methoxy polyethylene glycol / epoetin beta. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegademase",
            "description": {
                "common": "pegvaliase, pegademase. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegaptanib",
            "description": {
                "common": "pegvaliase, pegaptanib. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegaspargase",
            "description": {
                "common": "pegvaliase, pegaspargase. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegfilgrastim",
            "description": {
                "common": "pegvaliase, pegfilgrastim. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon alfa 2a",
            "description": {
                "common": "pegvaliase, peginterferon alfa 2a. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon alfa 2b",
            "description": {
                "common": "pegvaliase, peginterferon alfa 2b. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon beta-1a",
            "description": {
                "common": "pegvaliase, peginterferon beta-1a. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegloticase",
            "description": {
                "common": "pegvaliase, pegloticase. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pegvisomant",
            "description": {
                "common": "pegvaliase, pegvisomant. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polyethylene glycol & electrolytes",
            "description": {
                "common": "pegvaliase, polyethylene glycol & electrolytes. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polyethylene glycol 400/propylene glycol ophthalmic",
            "description": {
                "common": "pegvaliase, polyethylene glycol 400/propylene glycol ophthalmic. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polyethylene glycol/electrolytes/sodium ascorbate/ascorbic acid",
            "description": {
                "common": "pegvaliase, polyethylene glycol/electrolytes/sodium ascorbate/ascorbic acid. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol",
            "description": {
                "common": "pegvaliase, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. \nComment: The majority of patients treated with pegvaliase develop anti-polyethylene glycol (PEG) IgM and IgG antibodies. Risk of coadministration with different PEGylated products is unknown. There is a case report of anaphylaxis following a medroxyprogesterone acetate injectable suspension that contained PEG 3350. Carefully read all drug labels, including OTC drugs to check contents for PEG. Note: Unable to include an exhaustive product list for this interaction."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Cough",
            "percent": "9"
        },
        {
            "name": "Diarrhea",
            "percent": "9"
        },
        {
            "name": "Anxiety",
            "percent": "5"
        },
        {
            "name": "Alopecia",
            "percent": "5"
        },
        {
            "name": "Nasal congestion",
            "percent": "4"
        },
        {
            "name": "Hs",
            "percent": "0.287"
        },
        {
            "name": "CRP above",
            "percent": "6"
        },
        {
            "name": "mg",
            "percent": "10"
        },
        {
            "name": "dL over a",
            "percent": null
        },
        {
            "name": "month period",
            "percent": null
        }
    ]
}